1. Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR).
- Author
-
Pastor JC, Rodríguez E, Marcos MA, and Lopez MI
- Subjects
- Animals, Dexamethasone therapeutic use, Disease Models, Animal, Drug Therapy, Combination, Methylprednisolone therapeutic use, Rabbits, Vitreoretinopathy, Proliferative pathology, Atropine therapeutic use, Colchicine therapeutic use, Diclofenac therapeutic use, Epinephrine therapeutic use, Glucocorticoids therapeutic use, Vitreoretinopathy, Proliferative drug therapy
- Abstract
Purpose: This study was designed to evaluate the efficacy of a combined treatment, previously used to prevent fibrosis after glaucoma surgery, to inhibit an experimental model of proliferative vitreoretinopathy (PVR)., Methods: Two groups of albino rabbits were used. In the control group (group 1, n = 14), experimental PVR was induced using vitrectomy, retinotomies, cryotherapy and intraocular injection of platelet-rich plasma. In the experimental group (group 2, n = 15), after PVR was induced, the following treatment was administered for 4 weeks: systemic methylprednisolone, sodium diclofenac and colchicine combined with topical atropine 1%, adrenaline 10% and dexamethasone phosphate 0.1%. Follow- up consisted of fundus examination for 4 weeks. Results were classified according to Fastenberg's classification. Only retinal detachments were considered to compare the two groups. Nonparametric test was used., Results: Retinal detachments were observed in 85.7% of group 1 and 33.3% of group 2 at the end of the follow-up (p<0.01). No major systemic complications were observed., Conclusions: Combined therapy seems to be useful for treating experimental PVR., (Copyright 2000 S. Karger AG, Basel.)
- Published
- 2000
- Full Text
- View/download PDF